| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/1756-185X.12999 |
| P698 | PubMed publication ID | 28205331 |
| P50 | author | Reza Fadaei | Q59683067 |
| Mahdi Mahmoudi | Q43257957 | ||
| Saeed Aslani | Q59527712 | ||
| P2093 | author name string | Ahmad Reza Jamshidi | |
| P2860 | cites work | Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk | Q24630394 |
| Concept of vulnerable/unstable plaque | Q27687028 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Cholesterol, inflammation and innate immunity | Q28086912 | ||
| Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment | Q28175505 | ||
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
| Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci | Q28281906 | ||
| Immunity, atherosclerosis and cardiovascular disease | Q28688590 | ||
| Inflammation, atherosclerosis, and coronary artery disease | Q29547232 | ||
| Evolving concepts of rheumatoid arthritis | Q29618020 | ||
| Adipocytokines: mediators linking adipose tissue, inflammation and immunity | Q29619393 | ||
| Tobacco-smoking-related differential DNA methylation: 27K discovery and replication | Q33860650 | ||
| Cytokine pathways and joint inflammation in rheumatoid arthritis | Q33939087 | ||
| Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E | Q33962949 | ||
| Genetic susceptibility to cardiovascular diseases | Q34048878 | ||
| The coxibs, selective inhibitors of cyclooxygenase-2. | Q34086325 | ||
| Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics | Q34233328 | ||
| Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities | Q34245387 | ||
| Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 | ||
| Scavenger receptors in innate immunity | Q34493073 | ||
| Update on acute coronary syndromes: the pathologists' view | Q34646452 | ||
| Associations between APOE genotypes and disease susceptibility, joint damage and lipid levels in patients with rheumatoid arthritis | Q34683913 | ||
| IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial | Q34795777 | ||
| Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease | Q35377706 | ||
| Clinical utility of the anti-CCP assay in patients with rheumatic diseases | Q35553110 | ||
| Matrix metalloproteinases A review of their structure and role in acute coronary syndrome | Q35557333 | ||
| Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. | Q35637875 | ||
| Patterns of cardiovascular risk in rheumatoid arthritis | Q35638493 | ||
| Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis | Q35821357 | ||
| Resistin: functional roles and therapeutic considerations for cardiovascular disease | Q35859749 | ||
| Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies | Q35863952 | ||
| Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab | Q35954629 | ||
| Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. | Q36031031 | ||
| Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy | Q36113215 | ||
| Inflammation in atherosclerosis | Q36174933 | ||
| Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. | Q36190844 | ||
| Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation | Q36465464 | ||
| COX-2 and atherosclerosis. | Q36512084 | ||
| Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. | Q36591918 | ||
| Healthy endothelium: the scientific basis for cardiovascular health promotion and chronic disease prevention | Q36710482 | ||
| Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register | Q36732112 | ||
| Systematic functional regulatory assessment of disease-associated variants. | Q36915402 | ||
| Pathway analysis of seven common diseases assessed by genome-wide association | Q37014849 | ||
| Endothelial dysfunction: the early predictor of atherosclerosis. | Q37042021 | ||
| Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease | Q37078045 | ||
| Recent advances in the genetics of RA susceptibility | Q37080741 | ||
| Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis | Q37245188 | ||
| Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity. Association with genetic polymorphisms | Q37323564 | ||
| Rheumatoid arthritis and smoking: putting the pieces together | Q37350863 | ||
| ??? | Q28295371 | ||
| Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? | Q37362717 | ||
| Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages | Q37413355 | ||
| Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis | Q37466366 | ||
| Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis | Q37476528 | ||
| Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. | Q37570619 | ||
| Genetic susceptibility to rheumatoid arthritis: an emerging picture | Q37605649 | ||
| The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review | Q37640953 | ||
| Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis | Q37790040 | ||
| Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis | Q37801353 | ||
| Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review | Q37808889 | ||
| What's new in our understanding of the role of adipokines in rheumatic diseases? | Q37909903 | ||
| Vascular function and morphology in rheumatoid arthritis: a systematic review | Q37934239 | ||
| Stroke risk and NSAIDs: a systematic review of observational studies | Q37942486 | ||
| Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis | Q37977885 | ||
| Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis | Q37998219 | ||
| Mechanisms of endothelial dysfunction in rheumatoid arthritis: lessons from animal studies | Q38181283 | ||
| Mechanisms of plaque formation and rupture. | Q38218000 | ||
| Rheumatoid arthritis and metabolic syndrome | Q38236740 | ||
| Atherosclerosis in rheumatoid arthritis: is it all about inflammation? | Q38396964 | ||
| TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation | Q39887996 | ||
| Tumor necrosis factor-alpha -mediated protein kinases in regulation of scavenger receptor and foam cell formation on macrophage | Q40857572 | ||
| Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than | Q41201384 | ||
| A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination | Q42676934 | ||
| Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis | Q43049221 | ||
| Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events | Q44216708 | ||
| The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis | Q44882366 | ||
| Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers | Q46749515 | ||
| Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. | Q51377213 | ||
| The mRNA Expression and Circulating Levels of Visfatin and Their Correlation with Coronary Artery Disease Severity and 25-Hydroxyvitamin D. | Q53317451 | ||
| Proinflammatory HLA-DRB1*01-haplotype predisposes to ST-elevation myocardial infarction. | Q53669495 | ||
| Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. | Q53725487 | ||
| Impaired Antiatherogenic Functions of High-density Lipoprotein in Patients with Ankylosing Spondylitis. | Q54255456 | ||
| A tale of two diseases: atherosclerosis and rheumatoid arthritis. | Q54448410 | ||
| Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. | Q55049410 | ||
| Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug–induced clinical remission: Evidence from an imaging study may explain structural progression | Q56420367 | ||
| Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study | Q57232023 | ||
| TNFA −308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis | Q57307074 | ||
| Natural regulatory T cells control the development of atherosclerosis in mice | Q58149268 | ||
| Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study | Q58160099 | ||
| P433 | issue | 3 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| atherosclerosis | Q12252367 | ||
| P304 | page(s) | 287-297 | |
| P577 | publication date | 2017-02-16 | |
| P1433 | published in | International Journal of Rheumatic Diseases | Q15764244 |
| P1476 | title | New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis | |
| P478 | volume | 20 |
| Q55431083 | An unfavorable body composition is common in early arthritis patients: A case control study. |
| Q48141377 | Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease. |
| Q61806794 | Association study between KIR polymorphisms and rheumatoid arthritis disease: an updated meta-analysis |
| Q55413719 | Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. |
| Q91776881 | Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions |
| Q90195194 | Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis |
| Q49282700 | Effects of a 12-week cardiovascular rehabilitation programme on systemic inflammation and traditional coronary artery disease risk factors in patients with rheumatoid arthritis (CARDIA trial): a randomised controlled trial |
| Q50085156 | Endothelium-derived contraction in a model of rheumatoid arthritis is mediated via angiotensin II type 1 receptors |
| Q58744087 | Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines |
| Q59799935 | Potential role of platelets for atherosclerotic events in rheumatoid arthritis |
| Q47243850 | Single nucleotide polymorphism of Methyl-CpG-binding protein 2 gene associates with juvenile idiopathic arthritis |
| Q90148590 | The Protective Effect of Different Polar Solvent Extracts of Er Miao San on Rats with Adjuvant Arthritis |
| Q45804014 | The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis. |
| Q89996474 | The Role of Mesenchymal Stem Cells in Atherosclerosis: Prospects for Therapy via the Modulation of Inflammatory Milieu |
Search more.